Form 8-K - Current report:
SEC Accession No. 0001683168-24-008794
Filing Date
2024-12-17
Accepted
2024-12-17 16:57:31
Documents
15
Period of Report
2024-12-17
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K actuate_8k.htm   iXBRL 8-K 36825
2 PRESS RELEASE OF ACTUATE THERAPEUTICS, INC. DATED DECEMBER 17, 2024 actuate_ex9901.htm EX-99.1 20194
6 GRAPHIC image_001.jpg GRAPHIC 2593
  Complete submission text file 0001683168-24-008794.txt   248574

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE actu-20241217.xsd EX-101.SCH 3106
4 XBRL LABEL FILE actu-20241217_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE actu-20241217_pre.xml EX-101.PRE 24187
17 EXTRACTED XBRL INSTANCE DOCUMENT actuate_8k_htm.xml XML 3803
Mailing Address 1751 RIVER RUN SUITE 400 FORT WORTH TX 76107
Business Address 1751 RIVER RUN SUITE 400 FORT WORTH TX 76107 847-986-4190
ACTUATE THERAPEUTICS, INC. (Filer) CIK: 0001652935 (see all company filings)

EIN.: 473044785 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42139 | Film No.: 241556456
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)